Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8623776 | 0.84 | L3MBTL1 (0.61) | L3MBTL1TDP1KMT2AFFAR1CTBP2 | |
| SCHEMBL4940818 | 0.83 | L3MBTL1 (0.62) | L3MBTL1TDP1KMT2ACTBP2RAB9A | |
| SCHEMBL2028391 | 0.82 | CA2 (0.65) | L3MBTL1TDP1CTBP2RAB9ANPC1 | |
| SCHEMBL7114566 | 0.82 | L3MBTL1 (0.58) | L3MBTL1TDP1KMT2AFFAR1CTBP2 | |
| SCHEMBL1411319 | 0.82 | L3MBTL1 (0.62) | L3MBTL1TDP1KMT2AFFAR1CTBP2 | |
| SCHEMBL2131696 | 0.81 | AKR1B1 (0.62) | L3MBTL1TDP1KMT2AFFAR1MEN1 | |
| SCHEMBL92022 | 0.81 | CA2 (0.62) | L3MBTL1TDP1KMT2AFFAR1CTBP2 | |
| SCHEMBL2525145 | 0.81 | CA2 (0.62) | L3MBTL1TDP1KMT2AFFAR1CTBP2 | |
| SCHEMBL12731519 | 0.80 | L3MBTL1 (0.61) | L3MBTL1TDP1KMT2AFFAR1CTBP2 | |
| SCHEMBL5486191 | 0.80 | TDP1 (0.43) | L3MBTL1TDP1FFAR1ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | L3MBTL1 4837/4885TDP1 4222/4885KMT2A 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.